Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105482 · ClinicalTrials.gov registry record · Phase 2
Targeted Interventions for Weight-Concerned Smokers
A Phase 2 study of Nicotine Dependence, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 1
- Study location
NCT00105482 is a Phase 2 study of Nicotine Dependence that has completed, run by Yale University. The registered enrollment target is 172 participants, roughly in line with the 184-participant average among 67 other Nicotine Dependence trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00105482, a Phase 2 study of Nicotine Dependence, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 1
- Study location
Study Summary
Weight gain after quitting smoking is an important barrier to treatment for many smokers. This study will test a drug called naltrexone with weight-concerned smokers to investigate whether or not this drug both improves smoking cessation quit rates and minimizes post quit weight gain.
Conditions Studied
Interventions
- DRUG Naltrexone
- BEHAVIORAL Behavioral counseling
- DRUG Transdermal nicotine replacement
Study Locations (1)
Connecticut
- Yale University School of Medicine Substance Abuse Treatment Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2005-01 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105482
The ClinicalTrials.gov registry entry for NCT00105482 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 184-participant average among 67 other Nicotine Dependence trials with a reported enrollment target. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 3 interventions - of which Naltrexone is the first listed.
NCT00105482 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00105482 about?
NCT00105482 is a clinical study titled "Targeted Interventions for Weight-Concerned Smokers". Weight gain after quitting smoking is an important barrier to treatment for many smokers. This study will test a drug called naltrexone with weight-concerned smokers to investigate whether or not this drug both improves smoking cessation quit rates and minimizes post quit weight gain.
What is the current status of trial NCT00105482?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2005-01. Estimated completion is 2009-10.
What conditions does trial NCT00105482 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT00105482?
The interventions under investigation include: Naltrexone (DRUG), Behavioral counseling (BEHAVIORAL), Transdermal nicotine replacement (DRUG).
Who is sponsoring clinical trial NCT00105482?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00105482 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Varenicline for E-cigarette Cessation
RECRUITING · Phase 2
-
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
COMPLETED · Phase 2
-
N-acetylcysteine for Tobacco Use Disorder
COMPLETED · Phase 2
-
Adaptive Pharmacotherapy for Smoking Cessation
COMPLETED · Phase 2
-
E-cigarette Nicotine Study
COMPLETED · Phase 2
-
Treatment of Smoking Among Individuals With PTSD
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.